LALinda Ahlkvist

Linda Ahlkvist

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Linda Ahlkvist has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Anders Valeur

    Department of Clinical SciencesBiomedical Center, Lund University, SE 22184 Lund, SwedenZealand Pharma A/SResearch and Development, DK-2600 Glostrup, Denmark

    1 shared publication
  • B Ahrén

    1 shared publication
  • B. Ahrén

    1 shared publication
  • Bilal Omar

    Department of Clinical Sciences, Biomedical Center, Lund University, SE 22184 Lund, Sweden2Zealand Pharma A/S, Research and Development, DK‐2600 Glostrup, Denmark

    1 shared publication
  • Bo Ahrén

    Department of Clinical Sciences, Biomedical Center, Lund University, SE 22184 Lund, Sweden2Zealand Pharma A/S, Research and Development, DK‐2600 Glostrup, Denmark

    1 shared publication
  • G. Pacini

    1 shared publication

Latest Publications

  • Defective insulin secretion by chronic glucagon receptor activation in glucose intolerant mice

    by Linda Ahlkvist, Bilal Omar, Anders Valeur, Keld Fosgerau, Bo Ahrén

    Stimulation of insulin secretion by short-term glucagon receptor (GCGR) activation is well characterized; however, the effect of long-term GCGR activation on β-cell function is not known, but of interest, since hyperglucagonemia occurs early during development of type 2 diabetes. Therefore, we examined whether chronic GCGR activation affects insulin secretion in glucose intolerant mice. To induce chronic GCGR activation, high-fat diet fed mice were continuously (2 weeks) infused with the stable glucagon analog ZP-GA-1 and challenged with oral glucose and intravenous glucose±glucagon-like peptide 1 (GLP1). Islets were isolated to evaluate the insulin secretory response to glucose±GLP1 and their pancreas were collected for immunohistochemical analysis. Two weeks of ZP-GA-1 infusion reduced insulin secretion both after oral and intravenous glucose challengesin vivoand in isolated islets. These inhibitory effects were corrected for by GLP1. Also, we observed increased β-cell area and islet size. We conclude that induction of chronic ZP-GA-1 levels in glucose intolerant mice markedly reduces insulin secretion, and thus, we suggest that chronic activation of the GCGR may contribute to the failure of β-cell function during development of type 2 diabetes.


  • Open Access

    Upregulated insulin secretion in insulin-resistant mice: evidence of increased islet GLP1 receptor levels and GPR119-activated GLP1 secretion

    by L Ahlkvist, K Brown, B Ahrén

    We previously demonstrated that the overall incretin effect and the β-cell responsiveness to glucagon-like peptide-1 (GLP1) are increased in insulin-resistant mice and may contribute to the upregulated β-cell function. Now we examined whether this could, first, be explained by increased islet GLP1 receptor (GLP1R) protein levels and, secondly, be leveraged by G-protein-coupled receptor 119 (GPR119) activation, which stimulates GLP1 secretion. Female C57BL/6J mice, fed a control (CD, 10% fat) or high-fat (HFD, 60% fat) diet for 8 weeks, were anesthetized and orally given a GPR119 receptor agonist (GSK706A; 10 mg/kg) or vehicle, followed after 10 min with gavage with a liquid mixed meal (0.285 kcal). Blood was sampled for determination of glucose, insulin, intact GLP1, and glucagon, and islets were isolated for studies on insulin and glucagon secretion and GLP1R protein levels. In HFD vs CD mice, GPR119 activation augmented the meal-induced increase in the release of both GLP1 (AUCGLP1 81±9.6 vs 37±6.9 pM×min, P=0.002) and insulin (AUCINS 253±29 vs 112±19 nM×min, PPP=0.014) but not in control mice. Islet GLP1R protein levels was higher in HFD vs CD mice (0.8±0.1 vs 0.5±0.1, P=0.035). In conclusion, insulin-resistant mice display increased islet GLP1R protein levels and augmented meal-induced GLP1 and insulin responses to GPR119 activation, which results in increased glucose elimination. We suggest that the increased islet GLP1R protein levels together with the increased GLP1 release may contribute to the upregulated β-cell function in insulin resistance.